Connection
Satish Garg to Diabetes Mellitus, Type 1
This is a "connection" page, showing publications Satish Garg has written about Diabetes Mellitus, Type 1.
|
|
Connection Strength |
|
 |
|
 |
|
17.016 |
|
|
|
-
Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 Jun; 27(6):430-438.
Score: 0.295
-
Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 Mar; 27(3):152-160.
Score: 0.294
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
Score: 0.291
-
Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep; 26(9):618-625.
Score: 0.278
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jun; 26(6):367-374.
Score: 0.277
-
Garg SK, Snell-Bergeon J, Kaur G, Beatson C. Challenges of GLP Analog Use for People with Type 1 Diabetes: Issues with Prior Approvals and Tips for Safer Use. Diabetes Technol Ther. 2024 Jun; 26(6):363-366.
Score: 0.275
-
Garg SK, McVean JJ. Development and Future of Automated Insulin Delivery (AID) Systems. Diabetes Technol Ther. 2024 Mar; 26(S3):1-6.
Score: 0.274
-
Bailey R, Calhoun P, Garg SK. Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange Registry. Diabetes Technol Ther. 2024 Mar; 26(3):156-160.
Score: 0.274
-
Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Mar; 26(3):184-189.
Score: 0.274
-
Garg SK, Polsky S. Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes. N Engl J Med. 2023 Oct 26; 389(17):1617-1619.
Score: 0.267
-
Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 01; 25(1):1-12.
Score: 0.253
-
Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
Score: 0.238
-
Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
Score: 0.231
-
Garg SK. Emerging Landscape of Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 09; 23(S3):S1-S4.
Score: 0.231
-
Rodbard D, Garg SK. Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 03; 23(3):221-226.
Score: 0.222
-
Shah VN, Garg SK. Standardized Hybrid Closed-Loop System Reporting. Diabetes Technol Ther. 2021 05; 23(5):323-331.
Score: 0.219
-
Peters AL, Garg SK. The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020 Jun; 22(6):449-453.
Score: 0.210
-
Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. Diabetes Technol Ther. 2020 06; 22(6):431-439.
Score: 0.210
-
Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020 07; 22(7):516-526.
Score: 0.209
-
Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
Score: 0.207
-
Garg K, Brackett S, Hirsch IB, Garg SK. NAFLD/NASH and Diabetes. Diabetes Technol Ther. 2020 Feb; 22(S1):S174-S186.
Score: 0.207
-
Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technol Ther. 2020 09; 22(9):666-673.
Score: 0.207
-
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019 09; 21(9):471-477.
Score: 0.201
-
Garg SK, Shah V. Closed-loop insulin delivery systems for patients with diabetes. Lancet Digit Health. 2019 05; 1(1):e2-e3.
Score: 0.196
-
Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2019 02; 21(S1):S4-S12.
Score: 0.193
-
Garg SK, Giordano D. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2019 02; 21(S1):S160-S171.
Score: 0.193
-
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 02; 21(2):66-72.
Score: 0.192
-
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
Score: 0.188
-
Garg SK, Peters AL, Buse JB, Danne T. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. Diabetes Technol Ther. 2018 09; 20(9):571-575.
Score: 0.187
-
Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
Score: 0.186
-
Garg SK, Akturk HK. A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. Diabetes Technol Ther. 2018 06; 20(6):391-394.
Score: 0.185
-
Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018 06; 20(6):395-402.
Score: 0.185
-
Garg SK, Rewers AH, Akturk HK. Ever-Increasing Insulin-Requiring Patients Globally. Diabetes Technol Ther. 2018 06; 20(S2):S21-S24.
Score: 0.184
-
Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S224-S232.
Score: 0.184
-
Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 06; 20(6):428-433.
Score: 0.184
-
Garg SK, Strumph P. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. N Engl J Med. 2018 03 08; 378(10):967-968.
Score: 0.181
-
Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technol Ther. 2018 02; 20(2):160-170.
Score: 0.180
-
Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2018 02; 20(S1):S3-S12.
Score: 0.180
-
Garg SK, Rewers AH, Akturk HK. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2018 02; 20(S1):S139-S153.
Score: 0.180
-
Thrasher J, Surks H, Nowotny I, Pierre S, Rotthaeuser B, Wernicke-Panten K, Garg S. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. J Diabetes Sci Technol. 2018 05; 12(3):680-686.
Score: 0.180
-
Garg SK, Polsky S. Continuous glucose monitoring in pregnant women with type 1 diabetes. Lancet. 2017 11 25; 390(10110):2329-2331.
Score: 0.175
-
Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Sim? R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348.
Score: 0.175
-
Garg SK. Expanding Treatment Options for Improving Health Outcomes in Type 1 Diabetes. Diabetes Technol Ther. 2017 Oct; 19(10):549-551.
Score: 0.175
-
Garg SK, Wernicke-Panten K, Rojeski M, Pierre S, Kirchhein Y, Jedynasty K. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. Diabetes Technol Ther. 2017 09; 19(9):516-526.
Score: 0.175
-
Garg SK, Akturk HK. The Future of Continuous Glucose Monitoring. Diabetes Technol Ther. 2017 06; 19(S3):S1-S2.
Score: 0.172
-
Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2017 02; 19(S1):S3-S10.
Score: 0.168
-
Garg SK, Giordano D, Gallo T, Shah VN. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2017 02; 19(S1):S128-S140.
Score: 0.168
-
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017 03; 19(3):155-163.
Score: 0.168
-
Polsky S, Giordano D, Voelmle MK, Garcetti R, Garg SK. Using technology to advance type 1 diabetes care among women during the reproductive years and in pregnancy. Postgrad Med. 2016 May; 128(4):418-26.
Score: 0.158
-
Bode BW, Garg SK. THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES. Endocr Pract. 2016 Feb; 22(2):220-30.
Score: 0.154
-
Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of diabetes: past, present, and future. Diabetes Technol Ther. 2014 Aug; 16(8):477-90.
Score: 0.141
-
Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther. 2014 Mar; 16(3):125-30.
Score: 0.136
-
Garg SK, Michels AW, Shah VN. Use of non-insulin therapies for type 1 diabetes. Diabetes Technol Ther. 2013 Nov; 15(11):901-8.
Score: 0.134
-
Bhide M, Grey JM, Moser EG, Garg SK. A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013 Jul; 15(7):533-7.
Score: 0.131
-
Garg SK. Standardization of self-monitoring of blood glucose and continuous glucose monitoring reporting. Diabetes Technol Ther. 2013 Mar; 15(3):193.
Score: 0.128
-
Garg SK. New therapies for diabetes management. Diabetes Technol Ther. 2013 Feb; 15 Suppl 1:S126-35.
Score: 0.127
-
Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
Score: 0.127
-
Garg SK, DiDomenico D, Switzer S. Ways to reduce cardiovascular disease in diabetes. Diabetes Technol Ther. 2012 Jun; 14 Suppl 1:S1-2.
Score: 0.122
-
Switzer SM, Moser EG, Rockler BE, Garg SK. Intensive insulin therapy in patients with type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2012 Mar; 41(1):89-104.
Score: 0.121
-
Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012 Jul; 97(1):16-26.
Score: 0.119
-
Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar; 14(3):205-9.
Score: 0.119
-
Garg SK. Rising epidemic of diabetes and hypertension in Asia. Diabetes Technol Ther. 2012 Jan; 14(1):1-2.
Score: 0.117
-
Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011 Mar; 34(3):574-9.
Score: 0.111
-
Garg S, Moser E, Dain MP, Rodionova A. Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther. 2010 Nov; 12(11):835-46.
Score: 0.109
-
Garg SK. Impact of insulin delivery devices in diabetes care. Diabetes Technol Ther. 2010 Jun; 12 Suppl 1:S1-3.
Score: 0.106
-
Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract. 2010 May-Jun; 16(3):486-505.
Score: 0.105
-
Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract. 2010 Mar; 87(3):348-53.
Score: 0.104
-
Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Technol Ther. 2009 Dec; 11(12):757-65.
Score: 0.102
-
Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz PY. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S5-S16.
Score: 0.100
-
Garg SK. The future of continuous glucose monitoring. Diabetes Technol Ther. 2009 Jun; 11 Suppl 1:S1-3.
Score: 0.099
-
Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009 Feb; 11(2):65-72.
Score: 0.096
-
Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 Mar; 32(3):436-8.
Score: 0.095
-
Garg SK, Naik RG. Long-acting insulin analogs versus human insulins. Diabetes Technol Ther. 2008 Oct; 10(5):331-2.
Score: 0.094
-
Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, Gutin RS, Gottlieb PA. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008 Oct; 10(5):369-75.
Score: 0.094
-
Garg SK. Role of emerging new technologies. Diabetes Technol Ther. 2008 Oct; 10(5):413-4.
Score: 0.094
-
Ellis SL, Naik RG, Gemperline K, Garg SK. Use of continuous glucose monitoring in patients with type 1 diabetes. Curr Diabetes Rev. 2008 Aug; 4(3):207-17.
Score: 0.093
-
Garg S, Kelly WC, Garg S. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes. Expert Rev Med Devices. 2008 Mar; 5(2):113-23.
Score: 0.090
-
Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec; 30(12):3023-5.
Score: 0.088
-
Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun; 9(3):203-10.
Score: 0.086
-
Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S48-56.
Score: 0.086
-
Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007; 3(3):245-54.
Score: 0.083
-
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan; 29(1):44-50.
Score: 0.078
-
Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother. 2005 Apr; 6(4):643-51.
Score: 0.074
-
Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care. 2005 Mar; 28(3):714-5.
Score: 0.074
-
Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005 Jan-Feb; 11(1):11-7.
Score: 0.073
-
Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct; 66(1):49-56.
Score: 0.071
-
Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004 Oct; 6(5):589-95.
Score: 0.071
-
Garg S, Chase HP. Treatment of adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2004 May; 17(5):805-6.
Score: 0.069
-
Weinzimer SA, Tamborlane WV, Chase HP, Garg SK. Continuous glucose monitoring in type 1 diabetes. Curr Diab Rep. 2004 Apr; 4(2):95-100.
Score: 0.069
-
Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar; 27(3):734-8.
Score: 0.069
-
Garg SK, Hoff HK, Chase HP. The role of continuous glucose sensors in diabetes care. Endocrinol Metab Clin North Am. 2004 Mar; 33(1):163-73, x-xi.
Score: 0.069
-
Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther. 2004 Feb; 6(1):9-15.
Score: 0.068
-
Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003 Dec; 143(6):737-40.
Score: 0.067
-
Kelly CB, Karanchi H, Yu JY, Leyva MJ, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Aston CE, Beisswenger PJ, Lyons TJ. Plasma AGE and Oxidation Products, Renal Function, and Preeclampsia in Pregnant Women with Type 1 Diabetes: A Prospective Observational Study. J Diabetes Res. 2023; 2023:8537693.
Score: 0.066
-
Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI. The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3. Diabetes Care. 2023 07 01; 46(7):e133-e135.
Score: 0.065
-
Chase HP, Pearson JA, Wightman C, Roberts MD, Oderberg AD, Garg SK. Modem transmission of glucose values reduces the costs and need for clinic visits. Diabetes Care. 2003 May; 26(5):1475-9.
Score: 0.065
-
Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract. 2003 May-Jun; 9(3):187-93.
Score: 0.065
-
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, N?rgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 03 04; 44(2):254-280.
Score: 0.064
-
Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM, Buckingham BA, Carroll J, Ceriello A, Chow E, Choudhary P, Close K, Danne T, Dutta S, Gabbay R, Garg S, Heverly J, Hirsch IB, Kader T, Kenney J, Kovatchev B, Laffel L, Maahs D, Mathieu C, Mauricio D, Nimri R, Nishimura R, Scharf M, Del Prato S, Renard E, Rosenstock J, Saboo B, Ueki K, Umpierrez GE, Weinzimer SA, Phillip M. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023 01; 11(1):42-57.
Score: 0.063
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
Score: 0.062
-
Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab. 2022 09; 24(9):1762-1769.
Score: 0.061
-
Brazg R, Garg SK, Bhargava A, Thrasher JR, Latif K, Bode BW, Bailey TS, Horowitz BS, Cavale A, Kudva YC, Kaiserman KB, Grunberger G, Reed JC, Chattaraj S, Zhang G, Shin J, Chen V, Lee SW, Cordero TL, Rhinehart AS, Vigersky RA, Buckingham BA. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial. Diabetes Technol Ther. 2022 08; 24(8):535-543.
Score: 0.060
-
Johnston-Brooks CH, Lewis MA, Garg S. Self-efficacy impacts self-care and HbA1c in young adults with Type I diabetes. Psychosom Med. 2002 Jan-Feb; 64(1):43-51.
Score: 0.059
-
Gottlieb PA, Frias JP, Peters KA, Chillara B, Garg SK. Optimizing insulin therapy in pregnant women with type 1 diabetes mellitus. Treat Endocrinol. 2002; 1(4):235-40.
Score: 0.059
-
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed? Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 03; 24(3):178-189.
Score: 0.059
-
Akturk HK, Snell-Bergeon J, Pyle L, Fivekiller E, Garg S, Cobry E. Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. J Diabetes Complications. 2021 11; 35(11):108030.
Score: 0.058
-
Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diab Vasc Dis Res. 2021 Jan-Feb; 18(1):1479164121995928.
Score: 0.055
-
Bode BW, Garg SK, Norwood P, Morales C, Hardy T, Liu R, Ignaut D. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technol Ther. 2021 01; 23(1):41-50.
Score: 0.053
-
Kelly CB, Wagner CL, Shary JR, Leyva MJ, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Aston CE, Lyons TJ. Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes. Nutrients. 2020 Jul 10; 12(7).
Score: 0.053
-
Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
Score: 0.051
-
Kelly CB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Basu A, Hammad SM, Aston CE, Lyons TJ. Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 10 01; 104(10):4743-4755.
Score: 0.050
-
Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 05; 42(5):919-930.
Score: 0.049
-
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019 06; 42(6):1147-1154.
Score: 0.048
-
Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 Sep; 41(9):1970-1980.
Score: 0.046
-
Bjornstad P, Maahs DM, Roncal CA, Snell-Bergeon JK, Shah VN, Milagres T, Ellis SL, Hatch M, Chung LT, Rewers MJ, Garg S, Cherney DZ, Pyle L, Nadeau KJ, Johnson RJ. Role of bicarbonate supplementation on urine uric acid crystals and diabetic tubulopathy in adults with type 1 diabetes. Diabetes Obes Metab. 2018 07; 20(7):1776-1780.
Score: 0.045
-
Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed? 670G Hybrid Closed-Loop System. Diabetes Technol Ther. 2017 Dec; 19(12):749-752.
Score: 0.044
-
Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Menard MK, Aston CE, Lyons TJ. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):120-127.
Score: 0.044
-
Kelly CB, Hookham MB, Yu JY, Lockhart SM, Du M, Jenkins AJ, Nankervis A, Hanssen KF, Henriksen T, Garg SK, Hammad SM, Scardo JA, Aston CE, Patterson CC, Lyons TJ. Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. Diabetologia. 2017 12; 60(12):2514-2524.
Score: 0.044
-
Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technol Ther. 2017 07; 19(7):391-399.
Score: 0.043
-
Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR. Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technol Ther. 2017 05; 19(5):288-292.
Score: 0.042
-
Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA. 2016 10 04; 316(13):1407-1408.
Score: 0.041
-
Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016 Nov; 19(11):1099-1106.
Score: 0.040
-
Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21.
Score: 0.040
-
Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, Liljenquist DR, Aleppo G, Buse JB, Kruger D, Bhargava A, Goland RS, Edelen RC, Pratley RE, Peters AL, Rodriguez H, Ahmann AJ, Lock JP, Garg SK, Rickels MR, Hirsch IB. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care. 2016 Apr; 39(4):603-10.
Score: 0.039
-
Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul; 38(7):1181-8.
Score: 0.037
-
Weiss R, Garg SK, Bode BW, Bailey TS, Ahmann AJ, Schultz KA, Welsh JB, Shin JJ. Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther. 2015 Aug; 17(8):542-7.
Score: 0.037
-
Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. J Diabetes Sci Technol. 2015 May 18; 9(5):1016-20.
Score: 0.037
-
Basu A, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Aston CE, Lyons TJ. Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy. Nutr Res. 2015 May; 35(5):421-30.
Score: 0.037
-
Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther. 2014 May; 16(5):277-83.
Score: 0.035
-
Klonoff DC, Bergenstal RM, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann A, Welsh JB, Lee SW. ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. J Diabetes Sci Technol. 2013 Jul 01; 7(4):1005-10.
Score: 0.033
-
Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18; 369(3):224-32.
Score: 0.033
-
Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013 Mar 01; 7(2):562-78.
Score: 0.032
-
Du M, Basu A, Fu D, Wu M, Centola M, Jenkins AJ, Hanssen KF, Garg SK, Hammad SM, Scardo JA, Aston CE, Lyons TJ. Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study. Diabetes Care. 2013 Jul; 36(7):2054-61.
Score: 0.032
-
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1489-97.
Score: 0.030
-
Basu A, Alaupovic P, Wu M, Jenkins AJ, Yu Y, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Dashti A, Aston CE, Lyons TJ. Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study. J Clin Endocrinol Metab. 2012 May; 97(5):1752-62.
Score: 0.030
-
Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, Nguyen X, Shin J, Welsh JB, Lee SW. The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011 Nov 01; 5(6):1466-71.
Score: 0.029
-
Azar M, Basu A, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Garg SK, Hammad SM, Scardo JA, Aston CE, Lyons TJ. Serum carotenoids and fat-soluble vitamins in women with type 1 diabetes and preeclampsia: a longitudinal study. Diabetes Care. 2011 Jun; 34(6):1258-64.
Score: 0.028
-
Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, Garg SK, Rewers M. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011 Feb; 34(2):454-8.
Score: 0.027
-
Maahs DM, Snell-Bergeon JK, Kinney GL, Wadwa RP, Garg S, Ogden LG, Rewers M. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications. 2007 Sep-Oct; 21(5):273-9.
Score: 0.022
-
Edelman SV, Garg S, Kolterman OG. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2.
Score: 0.021
-
Kretowski A, McFann K, Hokanson JE, Maahs D, Kinney G, Snell-Bergeon JK, Wadwa RP, Eckel RH, Ogden L, Garg S, Li J, Cheng S, Erlich HA, Rewers M. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes. 2007 Mar; 56(3):863-71.
Score: 0.021
-
Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95.
Score: 0.021
-
Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005 May; 28(5):1051-6.
Score: 0.019
-
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005 Mar; 28(3):533-8.
Score: 0.018
-
Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb; 28(2):301-6.
Score: 0.018
-
Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003 Nov; 52(11):2833-9.
Score: 0.017
-
Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct; 26(10):2923-8.
Score: 0.017
-
Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman RC. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics. 2003 Apr; 111(4 Pt 1):790-4.
Score: 0.016
-
Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Menard MK, Aston CE, Lyons TJ. Response to Comment on Kelly et al. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care 2018;41:120-127. Diabetes Care. 2018 06; 41(6):e102-e103.
Score: 0.012
-
Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, P?llinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 05 01; 128(5):1888-1902.
Score: 0.011
-
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, N?rgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 12; 40(12):1631-1640.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|